- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05612152
Choose2Quit: Improving Equity in Smoking Cessation for Low Income Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Our novel intervention, Choose2Quit, builds on our prior successes with the Ask, Advice, Connect study, but now 1) allows personalized choice of counseling modality (phone, text, web, in-person); 2) conveys the value and low/no-cost availability of medications to support quit attempt success and sends providers the patient's request in e-prescription to transmit to patient's pharmacy; 3) assesses patient's need to manage social barriers to quitting by linking them to Unite-US; and 4) uses an initial phone contact from a recognizable local number, will increase the engagement of patients in cessation treatment and in tobacco cessation. This study aims to:
- Test the effect of a traditional eReferral vs. a Choose2Quit personalized guidance and choice approach on the ability to contact patients, and the proportion of patients that initiate tobacco cessation treatment, use tobacco cessation medications and make quit attempts.
- Assess the impact of each intervention arm on equitable engagement in tobacco cessation treatment, medication use and quit outcomes across gender, race and age groups.
- Evaluate intervention experience from the patient perspective.
- Evaluate the cost to implement, and per engagement in each of the intervention arms.
The study is accomplished using a 2-arm randomized trial. Randomization into the traditional eReferral vs. Choose2Quit intervention arms will occur at the patient level with a 1:1 group assignment. Individuals that are ready to quit in the next 30 days and are interested in being connected with tobacco cessation resources will be randomized. Randomization of eligible patients occurs automatically with an electronic health record algorithm that routes the eReferral to the Quitline (traditional eReferral) or the Choose2Quit intervention. The Ask-Advise-Connect process is exactly the same for medical assistants; medical assistants and patients are blind to group assignment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Susan Flocke
- Phone Number: 216 965 5538
- Email: flocke@ohsu.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patient care visit to one of the participating primary care clinics during the study period
- reports current tobacco use
- reports interest in quitting tobacco in the next 30 days
- accepts offer of referral to tobacco cessation support
Exclusion Criteria:
- not interested in quitting in next 30 days
- not interested in assistance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Referral to Quitline
Patients who indicate they are ready to quit in the next 30 days are offered an electronic referral to the state quitline for tobacco cessation services.
|
An electronic referral to the state quitline is placed.
This prompts the quitline to proactively call the patient to enroll in counseling services.
|
Experimental: Choose2Quit
Patients who indicate they are ready to quit in the next 30 days are offered an electronic referral to the Choose2Quit tobacco treatment navigator who walks the patient through choices for tobacco cessation counseling, tobacco cessation medications and other supports (e.g.
texting, apps) and facilitates placing referrals, orders and providing information.
|
An electronic referral to the Choose2quit tobacco cessation navigator is placed.
This prompts the navigator to call the patient to review options for tobacco cessation counseling, tobacco cessation medications and other supports.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
receipt of tobacco cessation counseling
Time Frame: 4 weeks after referral
|
receipt of 1 or more tobacco cessation counseling sessions from referral sources
|
4 weeks after referral
|
receipt of tobacco cessation medications
Time Frame: within 4 weeks after referral
|
documentation of orders for nicotine replacement therapy, varenicline or bupropion in electronic health record
|
within 4 weeks after referral
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
7-day point prevalence abstinence
Time Frame: 8 weeks after referral
|
7-day point prevalence abstinence from tobacco use
|
8 weeks after referral
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RSG-18-137-01-CPPB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
University of VirginiaVirginia Foundation for Healthy YouthRecruitingTobacco Use | Electronic Cigarette Use | Tobacco Use CessationUnited States
-
Vanderbilt University Medical CenterCompletedTobacco Use | Tobacco Use Cessation
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
British American Tobacco (Investments) LimitedCompletedTobacco Use | Tobacco SmokingUnited States
-
Philip Morris Products S.A.CompletedSmoking | Tobacco Use | Tobacco SmokingUnited Kingdom
Clinical Trials on Referral to Quitline
-
Wayne State UniversityUnknownTobacco Use CessationUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedTobacco Smoking | Tobacco Use CessationUnited States
-
George Washington UniversityWithdrawn
-
New York UniversityRecruiting
-
University of California, DavisTobacco Related Disease Research Program; Breathe California of Sacramento-Emigrant... and other collaboratorsCompletedSmoking Cessation
-
NYU Langone HealthCompleted
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; National Center for Advancing Translational Sciences...TerminatedSmoking CessationUnited States
-
Lawson Health Research InstituteCanadian Institutes of Health Research (CIHR); AstraZenecaCompletedMyocardial Infarction | Coronary Disease | Unstable AnginaCanada
-
Centers for Disease Control and PreventionCompletedThe Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services.Contact Tracing | Chlamydia InfectionUnited States
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteCompleted